查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1683573

全球糖尿病前期市场研究报告 - 产业分析、规模、份额、成长、趋势和预测 2025 年至 2033 年

Global Prediabetes Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
出版日期: | 出版商: Value Market Research | 英文 108 Pages | 商品交期: 最快1-2个工作天内

价格

全球糖尿病前期市场规模预计将从 2024 年的 2.4076 亿美元增长到 2033 年的 4.7055 亿美元，在 2026 年至 2033 年的预测期内呈现 7.73% 的强劲年复合成长率(CAGR)。

随着糖尿病前期盛行率的不断上升以及人们对其健康影响的认识不断提高，全球糖尿病前期市场有望实现大幅成长。糖尿病前期的特征是血糖值升高，但不足以被归类为糖尿病，这种疾病影响着全世界数百万人。随着医疗保健提供者和患者认识到早期干预对于防止进展为 2 型糖尿病的重要性，对糖尿病前期筛检、诊断工具和管理解决方案的需求预计将大幅上升，从而促进这一关键市场的创新和投资。

此外，数位健康技术和个人化医疗的进步预计将进​​一步推动糖尿病前期市场的发展。行动健康应用程式、穿戴式装置和远距医疗平台的开发使个人能够监测血糖水平、追踪生活方式的变化并获得医疗保健专业人员的个人化指导。此外，人们越来越重视生活方式改变计划，包括改变饮食和体能锻炼，这推动了对综合管理解决方案的需求，使个人能够掌控自己的健康。随着医疗保健领域的不断发展，糖尿病前期解决方案市场对满足不同患者需求的创新产品和服务的需求可能会激增。

此外，对法规遵从性和公共卫生措施的日益关注预计将影响糖尿病前期市场的未来。随着政府和卫生组织实施旨在提高意识和促进预防措施的计划，对糖尿病前期筛检和管理解决方案的需求将持续上升。医疗保健提供者、技术开发商和监管机构之间的协作努力对于推动这些进步至关重要，确保糖尿病前期市场能够满足患者和医疗保健系统不断变化的需求。

我们的报告经过精心製作，为客户提供有关各个行业和市场的全面且可操作的见解。每份报告都包含几个关键部分，以确保彻底了解市场格局：

市场概览：市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本节探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准将市场细分为不同的细分市场。该分析强调了每个部分的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本节深入介绍领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，预测特定时期内的市场规模和成长趋势。这包括定量分析和图形表示来说明未来的市场轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前和新兴的市场趋势、技术创新和潜在投资领域。本节提供未来市场发展和成长前景的见解。

目录

第 1 章：前言

  • 报告描述
    • 客观的
    • 目标受众
    • 独特销售主张 (USP) 产品
  • 研究范围
  • 研究方法
    • 市场研究流程
    • 市场研究方法

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：糖尿病前期产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业趋势
  • 波特五力分析
  • 市场吸引力分析
    • 按药品类别进行市场吸引力分析
    • 按年龄分析市场吸引力
    • 市场吸引力分析：按地区

第四章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料製造商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球糖尿病前期市场分析：依药物类别

  • 按药物类别概述
  • 历史和预测数据
  • 按药物类别分析
  • 双胍类
  • 噻唑烷二酮类
  • 胰高血糖素样胜肽-1 激动剂 (GLP-1)
  • SGLT2 抑制剂
  • DPP-4 抑制剂
  • 其他的

第 6 章：全球糖尿病前期市场分析：依年龄组

  • 年龄层概览
  • 历史和预测数据
  • 年龄层分析
  • 儿童（12-18岁）
  • 成人（18-49 岁）
  • 老年人（50 岁以上）

第 7 章：全球糖尿病前期市场分析：按地区划分

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概述、历史和预测数据销售分析
    • 北美各细分市场销售分析
    • 北美各国销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概述、历史和预测数据销售分析
    • 欧洲各细分市场销售分析
    • 欧洲各国销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概述、历史和预测数据销售分析
    • 亚太地区分部销售分析
    • 亚太地区国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概述、历史和预测数据销售分析
    • 拉丁美洲各细分市场销售分析
    • 拉丁美洲各国销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东非洲销售分析
    • 概述、历史和预测数据销售分析
    • 中东非洲各细分市场销售分析
    • 中东非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东和非洲其他地区销售分析

第 8 章：糖尿病前期公司的竞争格局

  • 糖尿病前期市场竞争
  • 伙伴关係/合作/协议
  • 合併与收购
  • 新产品发布
  • 其他进展

第九章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • Novo Nordisk
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Valbiotis
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Resverlogix
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Caelus Health
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • SciMar
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Boston Therapeutics
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Aphaia Pharma
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • AstraZeneca
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol-Myers Squibb
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

注意 - 在公司简介中，财务细节和近期发展取决于可用性，对于私人公司，可能不予涵盖

Product Code: VMR112114025

Global Prediabetes Market size is anticipated to grow from USD 240.76 Million in 2024 to USD 470.55 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.73% during the forecast period of 2026 to 2033.

The global prediabetes market is poised for significant growth, driven by the increasing prevalence of prediabetes and the rising awareness of its health implications. Prediabetes, characterized by elevated blood sugar levels that are not yet high enough to be classified as diabetes, affects millions of individuals worldwide. As healthcare providers and patients recognize the importance of early intervention to prevent the progression to type 2 diabetes, the demand for screening, diagnostic tools, and management solutions for prediabetes is expected to rise substantially, fostering innovation and investment in this critical market.

Moreover, advancements in digital health technologies and personalized medicine are anticipated to further boost the prediabetes market. The development of mobile health applications, wearable devices, and telehealth platforms enables individuals to monitor their blood sugar levels, track lifestyle changes, and receive personalized guidance from healthcare professionals. Additionally, the growing emphasis on lifestyle modification programs, including dietary changes and physical activity, is driving the demand for comprehensive management solutions that empower individuals to take control of their health. As the healthcare landscape continues to evolve, the market for prediabetes solutions is likely to witness a surge in demand for innovative products and services that cater to diverse patient needs.

In addition, the increasing focus on regulatory compliance and public health initiatives is expected to shape the future of the prediabetes market. As governments and health organizations implement programs aimed at raising awareness and promoting preventive measures, the demand for prediabetes screening and management solutions will continue to rise. Collaborative efforts between healthcare providers, technology developers, and regulatory bodies will be essential in driving these advancements, ensuring that the prediabetes market remains responsive to the evolving needs of patients and healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Class

  • Diguanide
  • Thiazolidinediones
  • Glucagon-Like Peptide-1 Agonists (GLP-1)
  • SGLT2 Inhibitors
  • DPP-4 Inhibitors
  • Others

By Age Group

  • Children (12-18 Years)
  • Adults (18-49)
  • Elderly (50+)
  • COMPANIES PROFILED
  • Novo Nordisk
  • Valbiotis
  • RESVERLOGIX
  • Caelus Health
  • SciMar
  • Boston Therapeutics
  • Aphaia Pharma
  • AstraZeneca
  • Bristol-Myers Squibb
  • The above list can be customized.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PREDIABETES INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Age Group
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PREDIABETES MARKET ANALYSIS BY DRUG CLASS

  • 5.1 Overview by Drug Class
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Drug Class
  • 5.4 Diguanide Historic and Forecast Sales by Regions
  • 5.5 Thiazolidinediones Historic and Forecast Sales by Regions
  • 5.6 Glucagon-Like Peptide-1 Agonists (GLP-1) Historic and Forecast Sales by Regions
  • 5.7 SGLT2 Inhibitors Historic and Forecast Sales by Regions
  • 5.8 DPP-4 Inhibitors Historic and Forecast Sales by Regions
  • 5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PREDIABETES MARKET ANALYSIS BY AGE GROUP

  • 6.1 Overview by Age Group
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Age Group
  • 6.4 Children (12-18 Years) Historic and Forecast Sales by Regions
  • 6.5 Adults (18-49) Historic and Forecast Sales by Regions
  • 6.6 Elderly (50+) Historic and Forecast Sales by Regions

7 . GLOBAL PREDIABETES MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1. Overview, Historic and Forecast DataSales Analysis
    • 7.3.2. North America By Segment Sales Analysis
    • 7.3.3. North America By Country Sales Analysis
    • 7.3.4. United State Sales Analysis
    • 7.3.5. Canada Sales Analysis
    • 7.3.6. Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1. Overview, Historic and Forecast DataSales Analysis
    • 7.4.2. Europe by Segment Sales Analysis
    • 7.4.3. Europe by Country Sales Analysis
    • 7.4.4. United Kingdom Sales Analysis
    • 7.4.5. France Sales Analysis
    • 7.4.6. Germany Sales Analysis
    • 7.4.7. Italy Sales Analysis
    • 7.4.8. Russia Sales Analysis
    • 7.4.9. Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1. Overview, Historic and Forecast DataSales Analysis
    • 7.5.2. Asia Pacific by Segment Sales Analysis
    • 7.5.3. Asia Pacific by Country Sales Analysis
    • 7.5.4. China Sales Analysis
    • 7.5.5. India Sales Analysis
    • 7.5.6. Japan Sales Analysis
    • 7.5.7. South Korea Sales Analysis
    • 7.5.8. Australia Sales Analysis
    • 7.5.9. South East Asia Sales Analysis
    • 7.5.10. Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1. Overview, Historic and Forecast DataSales Analysis
    • 7.6.2. Latin America by Segment Sales Analysis
    • 7.6.3. Latin America by Country Sales Analysis
    • 7.6.4. Brazil Sales Analysis
    • 7.6.5. Argentina Sales Analysis
    • 7.6.6. Peru Sales Analysis
    • 7.6.7. Chile Sales Analysis
    • 7.6.8. Rest of Latin America Sales Analysis
  • 7.7. Middle East Africa Sales Analysis
    • 7.7.1. Overview, Historic and Forecast DataSales Analysis
    • 7.7.2. Middle East Africa by Segment Sales Analysis
    • 7.7.3. Middle East Africa by Country Sales Analysis
    • 7.7.4. Saudi Arabia Sales Analysis
    • 7.7.5. UAE Sales Analysis
    • 7.7.6. Israel Sales Analysis
    • 7.7.7. South Africa Sales Analysis
    • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PREDIABETES COMPANIES

  • 8.1. Prediabetes Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF PREDIABETES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Novo Nordisk
    • 9.3.1. Company Overview
    • 9.3.2. Company Revenue
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Valbiotis
    • 9.4.1. Company Overview
    • 9.4.2. Company Revenue
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. Resverlogix
    • 9.5.1. Company Overview
    • 9.5.2. Company Revenue
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. Caelus Health
    • 9.6.1. Company Overview
    • 9.6.2. Company Revenue
    • 9.6.3. Products
    • 9.6.4. Recent Developments
  • 9.7. SciMar
    • 9.7.1. Company Overview
    • 9.7.2. Company Revenue
    • 9.7.3. Products
    • 9.7.4. Recent Developments
  • 9.8. Boston Therapeutics
    • 9.8.1. Company Overview
    • 9.8.2. Company Revenue
    • 9.8.3. Products
    • 9.8.4. Recent Developments
  • 9.9. Aphaia Pharma
    • 9.9.1. Company Overview
    • 9.9.2. Company Revenue
    • 9.9.3. Products
    • 9.9.4. Recent Developments
  • 9.10. AstraZeneca
    • 9.10.1. Company Overview
    • 9.10.2. Company Revenue
    • 9.10.3. Products
    • 9.10.4. Recent Developments
  • 9.11. Bristol-Myers Squibb
    • 9.11.1. Company Overview
    • 9.11.2. Company Revenue
    • 9.11.3. Products
    • 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Class (USD MN)
  • Diguanide Market Sales by Geography (USD MN)
  • Thiazolidinediones Market Sales by Geography (USD MN)
  • Glucagon-Like Peptide-1 Agonists (GLP-1) Market Sales by Geography (USD MN)
  • SGLT2 Inhibitors Market Sales by Geography (USD MN)
  • DPP-4 Inhibitors Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Age Group (USD MN)
  • Children (12-18 Years) Market Sales by Geography (USD MN)
  • Adults (18-49) Market Sales by Geography (USD MN)
  • Elderly (50+) Market Sales by Geography (USD MN)
  • Global Prediabetes Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Prediabetes Report
  • Market Research Process
  • Market Research Methodology
  • Global Prediabetes Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Age Group
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • Diguanide Market Sales by Geography (USD MN)
  • Thiazolidinediones Market Sales by Geography (USD MN)
  • Glucagon-Like Peptide-1 Agonists (GLP-1) Market Sales by Geography (USD MN)
  • SGLT2 Inhibitors Market Sales by Geography (USD MN)
  • DPP-4 Inhibitors Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Age Group (USD MN)
  • Children (12-18 Years) Market Sales by Geography (USD MN)
  • Adults (18-49) Market Sales by Geography (USD MN)
  • Elderly (50+) Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.